RxDoctor Payments Data

Michael Burton, MD

Clinical Cardiac Electrophysiology · Fort Myers, FLNPI 1871557082

Payments from drug & device makers

$22,995in general payments, 2019–2025

Across 198 payments — averaging $116.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$20K
  • Boston Scientific$1K
  • Cardiva Medical, Inc.$640
  • Abbott$520
  • Philips North America LLC$117
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$90
  • plus $80 from 4 others

What the payments were for

  • Speaking & faculty fees$7,35032%
  • Travel & lodging$6,00226%
  • Food & beverage$9,57242%
  • Education$700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)131$20,297
Boston Scientific32$1,251
Cardiva Medical, Inc.16$640
Abbott8$520
Philips North America LLC1$117
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)6$90
Novartis1$23
DUSA Pharmaceuticals, Inc.1$22
Terumo Medical Corporation1$22
Pfizer1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,995 in reported general payments places this provider in the 35th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$267,397
Medicare patients
754
Services billed
2,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$135,223
XareltoRivaroxaban54$59,206
EntrestoSacubitril/Valsartan12$11,970
Dofetilide17$4,568
Flecainide Acetate95$4,562
Amiodarone Hcl59$1,156
ClopidogrelClopidogrel Bisulfate76$702
Metoprolol Succinate63$700
SotalolSotalol Hcl19$413
Rosuvastatin Calcium14$375
Carvedilol24$307
Atorvastatin Calcium35$302
Simvastatin18$246
Lisinopril28$228
Cephalexin44$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$135,223114 claims
NovartisEntresto$23$11,97012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →